Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

The seasonal flu vaccine is, essentially, the only known way to prevent influenza epidemics. However, this approach has limited efficacy due to the high diversity of influenza viruses. Several techniques could potentially overcome this obstacle. A recent first-in-human study of a chimeric hemaggluti...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-04, Vol.10 (5), p.709
Main Authors: Deviatkin, Andrei A, Simonov, Ruslan A, Trutneva, Kseniya A, Maznina, Anna A, Khavina, Elena M, Volchkov, Pavel Y
Format: Article
Language:English
Subjects:
Animals
circRNA
Clinical trials
Coronaviruses
COVID-19 vaccines
Disease transmission
Hemagglutinins
Hogs
Influenza
influenza virus
mRNA
mRNA vaccine
mRNA vaccines
Pandemics
Protein expression
Proteins
Public health
Review
RNA polymerase
Severe acute respiratory syndrome coronavirus 2
universal flu vaccine
Vaccine development
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The seasonal flu vaccine is, essentially, the only known way to prevent influenza epidemics. However, this approach has limited efficacy due to the high diversity of influenza viruses. Several techniques could potentially overcome this obstacle. A recent first-in-human study of a chimeric hemagglutinin-based universal influenza virus vaccine demonstrated promising results. The coronavirus pandemic triggered the development of fundamentally new vaccine platforms that have demonstrated their effectiveness in humans. Currently, there are around a dozen messenger RNA and self-amplifying RNA flu vaccines in clinical or preclinical trials. However, the applicability of novel approaches for a universal influenza vaccine creation remains unclear. The current review aims to cover the current state of this problem and to suggest future directions for RNA-based flu vaccine development.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10050709